Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
Open Access
- 9 November 2019
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in HemaSphere
- Vol. 3 (6), e310
- https://doi.org/10.1097/hs9.0000000000000310
Abstract
An abstract is unavailable. This article is available as a PDF only.This publication has 25 references indexed in Scilit:
- JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse modelBlood, 2014
- Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031Leukemia, 2014
- Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groupsHaematologica, 2012
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic LeukemiaCancer Cell, 2012
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of MyelofibrosisClinical Cancer Research, 2012
- Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac healthExpert Review of Hematology, 2011
- Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine ReceptorsCell Chemical Biology, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryBlood, 2009
- Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimensLeukemia & Lymphoma, 2008